NCT04331132View on ClinicalTrials.gov

Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction

NAUnknownINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

July 26, 2023

Conditions
Acute Heart Failure
Interventions
DRUG

Tolvaptan 15 MG

vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy

Trial Locations (1)

70000

RECRUITING

Cardiology Department, Ho Chi Minh City

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Vietnam

INDUSTRY

lead

Gia Dinh People Hospital

OTHER

NCT04331132 - Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction | Biotech Hunter | Biotech Hunter